167 related articles for article (PubMed ID: 37316414)
1. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Jindal T; Zhang L; Deshmukh P; Reyes K; Chan E; Kumar V; Zhu X; Maldonado E; Feng S; Johnson M; Angelidakis A; Kwon D; Desai A; Borno HT; Bose R; Wong A; Hong J; Carroll P; Meng M; Porten S; Aggarwal R; Small EJ; Fong L; Chou J; Friedlander T; de Kouchkovsky I; Koshkin VS
Clin Genitourin Cancer; 2023 Oct; 21(5):e394-e404. PubMed ID: 37316414
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Nagata Y; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Curr Oncol; 2024 Feb; 31(2):862-871. PubMed ID: 38392058
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
Tsai TH; Su PJ; Huang SY; Kuo MC; Lin CT; Wu CC; Luo HL; Chen CH; Chou CC; Liu TT; Huang CC; Tsai KL; Su YL
BMC Cancer; 2023 Sep; 23(1):871. PubMed ID: 37715113
[TBL] [Abstract][Full Text] [Related]
4. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.
Tripathi N; Jo Y; Tripathi A; Sayegh N; Li H; Nussenzveig R; Haaland B; Thomas VM; Gupta S; Maughan BL; Swami U; Pal SK; Grivas P; Agarwal N; Sirohi D
Urol Oncol; 2022 Nov; 40(11):493.e1-493.e7. PubMed ID: 35918248
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Harada M; Negishi T; Sakamoto N; Song Y; Hori Y; Tomoda T; Tamura S; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Clin Genitourin Cancer; 2022 Oct; 20(5):499.e1-499.e8. PubMed ID: 35624001
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato A; Kimuro R; Ohno D; Tanigawa K; Kuretake K; Matsukawa T; Takaba T; Jojima K; Harada M; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N; Miyamoto H
Anticancer Res; 2023 Sep; 43(9):4055-4060. PubMed ID: 37648337
[TBL] [Abstract][Full Text] [Related]
12. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors.
Chawla NS; Sayegh N; Tripathi N; Govindarajan A; Zengin ZB; Phillip EJ; Dizman N; Meza L; Muddasani R; Chehrazi-Raffle A; Malhotra J; Hsu J; Agarwal N; Pal SK; Tripathi A
Clin Genitourin Cancer; 2023 Feb; 21(1):69-75. PubMed ID: 36509613
[TBL] [Abstract][Full Text] [Related]
13. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract][Full Text] [Related]
14. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Barata P; Sonpavde G; Wright JL; Yu EY; Montgomery RB; Hsieh AC; Grivas P; Khaki AR
Clin Genitourin Cancer; 2022 Dec; 20(6):558-567. PubMed ID: 36155169
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
16. Somatic alterations of
Jindal T; Zhu X; Bose R; Kumar V; Maldonado E; Deshmukh P; Shipp C; Feng S; Johnson MS; Angelidakis A; Kwon D; Borno HT; de Kouchkovsky I; Desai A; Aggarwal R; Fong L; Small EJ; Wong A; Porten S; Chou J; Friedlander T; Koshkin VS
Front Oncol; 2023; 13():1161089. PubMed ID: 37091148
[TBL] [Abstract][Full Text] [Related]
17. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M; Narita S; Matsui Y; Kanda S; Hidaka Y; Abe H; Tsuzuki T; Ito K; Kojima T; Kato M; Hatakeyama S; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Morita S; Habuchi T; Ogawa O; Nishiyama H; Kitamura H; Kobayashi T;
BJU Int; 2022 Aug; 130(2):226-234. PubMed ID: 34110696
[TBL] [Abstract][Full Text] [Related]
18. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
19. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
20. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Teo MY; Al-Ahmadie H; Seier K; Tully C; Regazzi AM; Pietzak E; Solit DB; Tickoo S; Reuter V; Cha EK; Herr H; Donahue T; Donat SM; Dalbagni G; Bochner BH; Funt S; Iyer GV; Bajorin DF; Ostrovnaya I; Rosenberg JE
Br J Cancer; 2021 Mar; 124(7):1214-1221. PubMed ID: 33473164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
